Evidence map›Paper›PMID 32433950›Full record

ArticleImmunity2020

Endocrine Autoimmune Disease as a Fragility of Immune Surveillance against Hypersecreting Mutants.

Yael Korem Kohanim, Avichai Tendler, Avi Mayo, Nir Friedman, Uri Alon

Abstract read
In one paragraph

Article in Immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Clonally expanded CD38Science immunology · 2023
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Activation pathways that drive CD4Immunological reviews · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yael Korem KohanimDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel.
Avichai TendlerDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel.
Avi MayoDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel.
Nir FriedmanDepartment of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.
Uri AlonDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel. Electronic address: uri.alon@weizmann.ac.il.

Funding

Cancer Research UK 27145
6 · The paper itself

Abstract

Some endocrine organs are frequent targets of autoimmune attack. Here, we addressed the origin of autoimmune disease from the viewpoint of feedback control. Endocrine tissues maintain mass through feedback loops that balance cell proliferation and removal according to hormone-driven regulatory signals. We hypothesized the existence of a dedicated mechanism that detects and removes mutant cells that missense the signal and therefore hyperproliferate and hypersecrete with potential to disrupt organismal homeostasis. In this mechanism, hypersecreting cells are preferentially eliminated by autoreactive T cells at the cost of a fragility to autoimmune disease. The "autoimmune surveillance of hypersecreting mutants" (ASHM) hypothesis predicts the presence of autoreactive T cells in healthy individuals and the nature of self-antigens as peptides from hormone secretion pathway. It explains why some tissues get prevalent autoimmune disease, whereas others do not and instead show prevalent mutant-expansion disease (e.g., hyperparathyroidism). The ASHM hypothesis is testable, and we discuss experimental follow-up.

Indexed as

AnimalsAutoimmune DiseasesCell ProliferationDiabetes Mellitus, Type 1Endocrine GlandsEndocrine SystemFemaleHumansImmunologic SurveillanceMaleMutationT-Lymphocytesautoimmune diseasecircuit motifHashimoto’s thyroiditishyperparathyroidismhypersecreting adenomaimmune surveillanceprimary biliary cirrhosissystems biologytype 1 diabetesvitiligo

Identifiers

PMID32433950
PMCPMC7237888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.